GlobeNewswire Clinical StudiesOriginal article
Prime Medicine Announces U.S. FDA Clearance of Investigational New Drug Application for PM577a in H1069Q-mutated Wilson Disease
RegulatoryapprovedPM577aPositive
AI Analysis
Summary
Prime Medicine announced FDA clearance of its IND application for PM577a, a therapy targeting the H1069Q mutation in Wilson Disease, enabling initiation of a Phase 1/2 clinical program. The clearance, combined with a previously cleared CTA, establishes a global clinical development pathway for this rare disease treatment.
Clinical Trial Data
Phase
1/2
Outcome Details
FDA clearance of Investigational New Drug Application
Importance:7/10
Sentiment:
0.80
FDA clearanceIND approvalWilson Diseasegene therapyPhase 1/2rare disease
Read the original article
Published by GlobeNewswire Clinical Studies on July 23, 2026 8:05 PM